TY - JOUR
T1 - The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice
AU - Day, Julia
AU - Antony, Anna
AU - Tillett, William
AU - Coates, Laura C
N1 - Funding Information:
We declare no competing interests related to this work. Outside of this work, JD declares no competing interests. AA declares support for attending meetings and travel from Roche and Janssen. WT has received grants and research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen Novartis, and UCB; consulting fees, honoraria for lectures, support for attending meetings and travel, and participation in advisory boards from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB.. LCC has received grants and research support from AbbVie, Amgen, Celgene, Eli Lilly, Novartis and Pfizer; received payment for lectures from AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer and UCB; support for attending meetings and travel from Janssen; participation in advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer and UCB; and is chair of the British Psoriatic Arthritis consortium.
Funding Information:
LCC is funded by a National Institute for Health Research Clinician Scientist award. The work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR or the Department of Health.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/3/31
Y1 - 2022/3/31
N2 - Psoriatic arthritis is a heterogeneous condition with substantial challenges in optimising outcome measures for both clinical trials and daily practice. As with other inflammatory arthritides, there is no gold standard instrument for measuring disease activity or impact, both of which are key to evaluate therapeutic approaches in trials and monitor disease in daily practice. A wide range of domains have been highlighted in the Outcome Measures in Rheumatology (OMERACT) core domain set for psoriatic arthritis; reflecting the disease involvement in multiple tissues (joints, tendons, skin, and spine) and the heterogenous impact of the disease on individuals. This Review summarises the current evidence around outcome measure selection, considering factors such as unidimensional versus multidimensional outcomes, continuous versus binary measures, and the feasibility of these approaches in trials compared with clinical practice.
AB - Psoriatic arthritis is a heterogeneous condition with substantial challenges in optimising outcome measures for both clinical trials and daily practice. As with other inflammatory arthritides, there is no gold standard instrument for measuring disease activity or impact, both of which are key to evaluate therapeutic approaches in trials and monitor disease in daily practice. A wide range of domains have been highlighted in the Outcome Measures in Rheumatology (OMERACT) core domain set for psoriatic arthritis; reflecting the disease involvement in multiple tissues (joints, tendons, skin, and spine) and the heterogenous impact of the disease on individuals. This Review summarises the current evidence around outcome measure selection, considering factors such as unidimensional versus multidimensional outcomes, continuous versus binary measures, and the feasibility of these approaches in trials compared with clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85124008815&partnerID=8YFLogxK
U2 - 10.1016/S2665-9913(21)00349-0
DO - 10.1016/S2665-9913(21)00349-0
M3 - Review article
VL - 4
SP - e220-e228
JO - The Lancet Rheumatology
JF - The Lancet Rheumatology
SN - 2665-9913
IS - 3
ER -